Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
On 13 June 2018, Genentech, Inc. issued a press release announcing that the US FDA had approved the antiangiogenesis drug, bevacizumab, in combination with chemotherapy for frontline and maintenance therapy for women with newly diagnosed ovarian cancer. Regulatory approval was based on the National Cancer Institute-sponsored Gynecologic Oncology Group (GOG) protocol 0218, the Phase III, randomized, placebo-controlled, double-blind, multi-center and multi-national clinical trial that met its primary end point, progression-free survival. Bevacizumab is now approved in the frontline, platinum-sensitive recurrent and platinum-resistant recurrent settings for epithelial ovarian cancer. This review will address the broad range of clinical trials addressing the efficacy of bevacizumab use in ovarian cancer.
Women & Children
Haunschild, Carolyn E and Tewari, Krishnansu S, "Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer." (2019). Articles, Abstracts, and Reports. 2550.